Heidelberg

• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-507039-39-00 5 2024-03-22 Moderate to Severe Plaque Psoriasis
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• A Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with Specific KIT Exon Mutations Who Were … Recruiting
  2022-503058-37-00 5 2023-11-10 Advanced Gastrointestinal Stromal Tumor
• A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting
  2023-504247-13-00 4 2023-10-17 Small Cell Lung Cancer
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• OLE study in participants with pulmonary arterial hypertension Recruiting
  2023-505539-11-00 10 2023-04-06 Pulmonary Arterial Hypertension
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting
  2022-502503-30-00 5 2022-12-15 Acute lymphoblastic leukemia
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting
  2023-509331-83-00 5 2021-07-28 complement 3 glomerulopathy
• Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the … Recruiting
  2022-501677-39-00 5 2021-05-25 Adolescent Renal Allografts
• Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXC. Recruiting
  2024-512259-19-00 4 2021-04-08 Primary Hyperoxaluria
• A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Recruiting
  2023-506471-10-00 5 2019-10-04 Secondary hyperparathyroidism (SHPT) in pediatric patients with chroni
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 7 2015-01-20 Solid Tumors
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer
• PREFer Recruiting
  2024-520138-31-00 4 2026-06-01 Early-stage favorable classic Hodgkin lymphoma
• NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll … Recruiting
  2025-522091-84-00 4 2026-05-29 Merkel Cell Carcinoma
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma

Showing 97–120 of 735 trials